Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

• Published in: Transplantation and cellular therapy Vol. 29; no. 7; pp. 440 - 448
• Main Authors: Hoffmann, Marc S., Hunter, Bradley D., Cobb, Patrick W., Varela, Juan C., Munoz, Javier
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2023
• Subjects: Antigens, CD19 - therapeutic use; Cell- and Tissue-Based Therapy; Chimeric antigen receptor T cells; Diffuse large B cell lymphoma; Humans; Lymphoma, Large B-Cell, Diffuse - therapy; Lymphoma, Non-Hodgkin - chemically induced; Lymphoma, Non-Hodgkin - drug therapy; Neoplasm Recurrence, Local - drug therapy; Oncologists; Receptors, Chimeric Antigen - therapeutic use; Referral; Referral and Consultation; Retrospective Studies; United States; United States; Oncologists; Diffuse large B cell lymphoma; Chimeric antigen receptor T cells; Referral

•Chimeric antigen receptor (CAR) T cell therapy has shown efficacy and a manageable safety profile in relapsed/refractory diffuse large B cell lymphoma.•Several logistical/financial barriers prevent timely access to CAR-T therapy.•Collaboration between oncologists and treatment centers can overcome...